rather than "no body cares". Price appears to be working back to prior close, and the day is not over yet. By the way, FMR filed their 13G for 12/31 and they also increased MACK in Q4 by over 600,000 shares taking their ownership to 14.99%. 5 major Institutions collectively bought more than 4 million shares in Q4.
This failure of INCY immuno-oncology therapy shows the complex nature of cancer treatment design. This should have a positive impact in time for MACK as their trials readout with positive data.
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.
Following these results, and the previously announced interim analysis of the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafinib in patients with metastatic colorectal cancer and high C-reactive protein (CRP), ongoing Incyte-sponsored trials of ruxolitinib in solid tumors will be discontinued, including the Phase 3 JANUS 2 study in pancreatic cancer, the Phase 2 sub-study in patients with metastatic colorectal cancer and low CRP and the Phase 2 studies in breast and lung cancer. Incyte’s dose finding study of INCB39110 (a selective JAK1 inhibitor) as first-line treatment for metastatic pancreatic cancer, will also be discontinued. Incyte will work with investigators to appropriately conclude these studies in a manner consistent with the best interest of each patient. Data from these studies will be analyzed and shared with the scientific community over the coming months.
EMA Pharmacovigilance Risk Assessment Committee is currently reviewing the Risk Management Plan at their Feb 8-11th meeting. Maybe we hear something soon. Once we get a positive opinion, there is a 67 day period for EU to make final approval.
Options granted, not shares purchased. He ad all other insiders are locked out until after they release Q4 earnings.
Now they are loaded with tons of cheap options, we can watch the price rise!
You are double counting shares. The 16,712,869 is the total held by all the funds you list, and some you don't, under FMR, LLC. Check NASDAQ Institutional Holdings
Now with Westfield, 3,129,242 share increase, ~10.09%, to 34,145,727 shares or 28.51%. Adding Fidelity, we see ~43% held by 5 highly regarded institutional investors.
Insiders can not trade in shares until after Q4 report. They have been locked out since early September 2015. The knowledge of the $175 million debt offering kept them from being able to trade after Q3 report in early November 2015, because release didn't come until 12/22/2015; which occurred after the December window closed heading into Q4 end.
by purchasing 744,254 additional shares and taking their ownership to 6.28% per 13G just filed.
Combined as of 12/31/2015 they own 26,889,912 shares or ~22.23% of the company; an increase of ~9.73% from 9/30/2015. We have yet to hear from Fidelity, but as of 9/30/2015 they owned 16,712,869 shares or ~14.6% of he company. Fidelity increased their holdings by 1.27% in Q3 over Q2. Some have suggested that management's choices have turned off investors, but I would contend that they have turned off traders and speculators. It would appear that large institutional "investors" are seeing the long term play here, so much that they lined up for the $175 million debt placement while buying shares.
The sooner we get Q4 report, insiders are allowed to trade, news from EU Oniyde filing and Onivyde PI trials surfaces, the sooner we break trend from XBI: IMHO.
You may want to loo into the data regarding MM-141 and the potentiating effects in combination with check point inhibitors; poster of MM-141 presented at AACR-NCI-EORTC 2015. Look under resources pre-clinical.
You may also want to look at the data presented at AACR-NCI-EORTC 2015; various combos of MM-121, MM-131, MM-141 with MM-151. Look under resources pre-clinical MM-151
This data was presented in November at CTT AACR-EORTC 2015. The poster is on the website under resources MM-151 pre-clinical posters. The article was just released, there may be a lag time to wen they can put it on the site under articles.
Given that approval came during the current down turn in biotech, there were some taken off guard by the black box warning on label, and we have yet to hear specifics on initial revenue, I am not as disappointed as you. I am looking forward to Q4 call, insider activity, EMA Onivye decision, PIII Onivyde Gastric trial, and Onivyde PI trial results.
Please refer to the weekly chart comparison between the two.
Say what you want about Mulroy, but IMHO he gave a great interview today on CNBC! He is not the loser many have claimed him to be; the panel participants were very much in tune with his points. These are the points he has been making for a while; the talking heads have stopped talking long enough to listen. Mulroy has been very much like a bee buzzing around a flower bud waiting for it to open so that it can be pollenated; today was one of those occasions where persistence may have finally paid off!